XO1 Ltd

Biotech company developing ichorcumab, an anti-thrombin antibody that delivers anticoagulation without bleeding

[UK Startup News @Ukstartupnews]

Janssen snaps up Cambridge ‘miracle’ antibody #startup @XO1pharma http://t.co/JjKnKXzBnY via @sharethis #medtech #ukstartupnews

[XO1 Ltd @XO1pharma]

"Ichorcumab provides an excellent complement to the Janssen cardiovascular portfolio," said Peter DiBattiste, Global Dev Head, CV, Janssen

[XO1 Ltd @XO1pharma]

Janssen Acquires XO1 Limited http://t.co/wtSxpjzn0p

[BioTrinity @biotrinity]

@Merck @Amgen, @JNJInnovation and @XO1pharma confirmed for @OBN_UK debate "Should Pharma Externalization go to 100%" http://t.co/VP3XuEN9yI

[XO1 Ltd @XO1pharma]

Notes significant benefit of Xarelto™ over aspirin or aspirin+clopidogrel BUT elevated bleeding risk limits use to most severe ACS cases

[XO1 Ltd @XO1pharma]

NICE publish final draft guidance recommending Xarelto™ ( $BAYN $JNJ) in severe ACS: http://t.co/pFjGQPLSbT

[XO1 Ltd @XO1pharma]

Unsurprising but not particularly useful data released on Brillanta. Issue not efficacy but differentiation from generic clopidogrel. $AZN

[FirstWord Pharma @fwpharma]

AstraZeneca's Brilinta cuts major cardiovascular thrombotic events: study http://t.co/kG6x9HTRAa $AZN #pharma

[XO1 Ltd @XO1pharma]

With concerns about stability of exposure and no identifiable advantages, this will be an insurmountable marketing challenge

[XO1 Ltd @XO1pharma]

FDA approves 3rd FXa inhibitor, edoxaban from Daiichi Sankyo: http://t.co/LsQAIIYiKt But with black box warning for use w/ renal impairment

[Andy Biotech @AndyBiotech]

DAPT (Dual AntiPlatelet Therapy) study data in NEJM http://t.co/40jtKRrzcS #AHA14

Editorial
http://t.co/NP8zatJHfG

[XO1 Ltd @XO1pharma]

Real-world data from Medicare suggests Pradaxa™ dabigatran is associated with greater risk of bleeds vs warfarin: http://t.co/CEK5r8lr6T

[XO1 Ltd @XO1pharma]

But in the messy real world, NOACs far easier to use optimally, so achieve better control of coagulation vs warfarin than seen in RCTs

[XO1 Ltd @XO1pharma]

UK probably has it right: RCTs tend to underestimate benefit with NOACs because perfectly-used NOAC equivalent to perfectly-used warfarin

[XO1 Ltd @XO1pharma]

Fascinating UK vs US difference in thinking: UK NICE encouraging Xarelto use in some ACS patients; in Jan FDA unanimously rejected ACS label

[FiercePharma @FiercePharma]

U.K. watchdogs back Bayer's Xarelto for heart attack patients http://t.co/2xMNgBq0sz #pharma by @CarlyHFierce

[FirstWord Pharma @fwpharma]

Physician Views: Can $PTLA's reversal agent act as growth catalyst for anticoagulants? http://t.co/yqrt0aWqGU #pharma

[XO1 Ltd @XO1pharma]

20% died from it but only 2% are worried about it - heart disease is a silent, but largely preventable, killer: http://t.co/dQWgyEzz3i

[XO1 Ltd @XO1pharma]

XO1 founders and CEO celebrate Cambridge News Top Innovator 2014 award this evening

[XO1 Ltd @XO1pharma]

NOACs certainly help but there is still plenty of unmet medical need - a drug with profile of ichorcumab could revolutionise this indication